

Published in final edited form as:

Immunity. 2013 April 18; 38(4): . doi:10.1016/j.immuni.2013.01.010.

# A network of High Mobility Group box transcription factors programs innate Interleukin-17 production

Nidhi Malhotra<sup>1,\*</sup>, Kavitha Narayan<sup>1,\*</sup>, Ok Hyun Cho<sup>1</sup>, Katelyn E. Sylvia<sup>1</sup>, Catherine Yin<sup>1</sup>, Heather Melichar<sup>1</sup>, Mehdi Rashighi<sup>2</sup>, Veronique Lefebvre<sup>3</sup>, John E. Harris<sup>2</sup>, Leslie J. Berg<sup>1</sup>, Joonsoo Kang<sup>1</sup>, and The Immunological Genome Project Consortium

<sup>1</sup>Department of Pathology, University of Massachusetts Medical School, Worcester, MA 01655, USA

<sup>2</sup>Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA

<sup>3</sup>Department of Cell Biology and Orthopaedic and Rheumatologic Center, Cleveland Clinic Lerner Research Institute, Cleveland, OH 44195, USA

# SUMMARY

How innate lymphoid cells (ILCs) in the thymus and gut become specialized effectors is unclear. The prototypic innate-like T cells (T 17) are a major source of interleukin-17 (IL-17). We demonstrate that T 17 cells are programmed by a gene regulatory network consisting of a quartet of High Mobility Group box (HMG) transcription factors, SOX4, SOX13, TCF1 and LEF1, and not by conventional TCR signaling. SOX4 and SOX13 directly regulated the two requisite T 17 cell-specific genes, *Rorc* and *Blk*, whereas TCF1 and LEF1 countered the SOX proteins and induced genes of alternate effector subsets. The T cell lineage specification factor TCF1 was also indispensable for the generation of IL-22 producing gut NKp46<sup>+</sup> ILCs and restrained cytokine production by Lymphoid Tissue inducer-like effectors. These results indicate that similar gene network architecture programs innate sources of IL-17, independent of anatomical origins.

## INTRODUCTION

ILCs and innate-like T cells (ILTC) producing IL-17 and IL-22 have emerged as the central players in mucosal immunity (Spits and Di Santo, 2011). Upon infection or alterations in cellular environments, ILCs lacking clonal antigen receptors and T cells expressing TCR rapidly produce effector cytokines and growth factors to promote pathogen clearance and tissue repair (O'Brien et al., 2009; Sonnenberg et al., 2011). TCR<sup>+</sup> ILTCs, similar to adaptive CD4<sup>+</sup> T cells, are segregated into effector subsets. However, unlike T effectors, TCR<sup>+</sup> effector subsets can be classified by the germline-encoded TCR chains and they are generated in the thymus (Jensen et al., 2008; Narayan et al., 2012; Ribot et al., 2009). More than half of V 2 TCR<sup>+</sup> (designated as V2) cells are intrathymically programmed to produce IL-17 (T 17) and express ROR t (*Rorc*), the primary transcription factor (TF) controlling IL-17 and IL-22 expression in all lymphocytes (Ivanov et al., 2006).

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

<sup>© 2013</sup> Elsevier Inc. All rights reserved.

Correspondence: joonsoo.kang@umassmed.edu (J.K.). \*\*These authors contributed equally to this work.

The emergent immature (CD24 $^{\rm hi}$ ) thymocyte subsets are further distinguished by TF networks that may specify effector fates. Most of these, including the HMG TFs SOX4 and SOX13, are expressed highly only at the early effector programming phase, their expression subsiding once effector capacity has been established at the mature (CD24 $^{\rm lo}$ ) stage. Whether this "early" wave of TFs dominantly programs ILTC subset function was unknown.

In addition to T 17 ILTCs, there are at least four other ROR t<sup>+</sup> ILTC and ILC subsets producing IL-17 and/or IL-22: TCR+ invariant NKT (Rachitskaya et al., 2008), Lymphoid Tissue inducer (LTi)-like (Sawa et al., 2010; Takatori et al., 2009), NK cell receptor expressing IL-22 producer (NKp46<sup>+</sup> NCR22 (Luci et al., 2009; Sanos et al., 2009; Satoh-Takayama et al., 2008; Vonarbourg et al., 2010)), and ILC17 cells (Buonocore et al., 2010), with the latter three subsets primarily localized in the gut associated lymphoid tissues (GALTs). How ILTCs and ILCs are programmed towards distinct effectors is not well understood. In particular, whether they share a unifying genetic blueprint for differentiation distinct from that specifying adaptive helper IL-17<sup>+</sup> T cells (Th17) is unknown. To answer these questions we determined the mechanism of innate effector programming of T 17 cells and its possible involvement in GALT ILC differentiation. We showed that the HMG TF TCF1 and LEF1, and their interacting partners SOX4 and SOX13, are expressed at particularly high amounts in the precursors of T 17 cells (Narayan et al., 2012). HMG TFs are transcription complex architectural proteins that bind to related sequences in the minor groove of DNA, and their cell type-specific combinatorial clustering at target genes cooperatively control transcription (Badis et al., 2009). TCF1, the nuclear effector of WNT signaling, is the best characterized HMG TF and is critical for T cell lineage specification downstream of Notch (Germar et al., 2011; Weber et al., 2011). We show here that the HMG TFs, not conventional TCR signaling, programmed IL-17 production in Moreover, TCF1 controlled cytokine production in postnatal GALT ILCs and was absolutely required for NCR22 ILC generation. These results identify shared gene network architecture centered on TCF1 underpinning IL-17 and IL-22 production by ILTCs and GALT ILCs.

# **RESULTS**

To determine if a common gene network controls innate lymphoid effector differentiation, we first identified genes selectively required to generate V2 T 17 cells. Emergent ILTC subsets are marked with gene expression profiles predictive of their eventual effector functions upon thymic egress (Narayan et al., 2012). Hence, the T effector subtype-specific core TF networks were candidates for specifying innate effector lineage fate. T 17 precursors, immature V2 (immV2, CD24hi) thymocytes, express genes encoding three HMG TFs, Sox4, Sox13 and Tcf7 (encoding TCF1), at the highest amounts, whereas the HMG TF Lef1 is expressed at similar amounts relative to other cell subsets (Narayan et al., 2012). Aside from Lef1, the HMG TF expression precedes that of TCR ((Melichar et al., 2007; Schilham et al., 1997; Verbeek et al., 1995; Weber et al., 2011), Immgen.org). To determine whether this expression pattern programs T 17 cell differentiation and function we examined T cell subsets in Sox13-/- (Melichar et al., 2007), Sox4-deficient and Tcf7-/- (Verbeek et al., 1995) mice and determined HMG TF chromatin occupancies in ex vivo T 17 precursors

### Sox13 programs V2 cell Tyδ17 differentiation

We found that Sox13-deficiency eliminated all V2 T 17 cells, whereas other effector subsets were largely intact (Figure 1). Sox13 was identified as a T cell-specific TF that interacts with TCF1 and LEF1 (Melichar et al., 2007), potentially modulating their function. Whereas all immature TCR<sup>+</sup> thymocytes express Sox13, T 17 precursors express the protein at the highest level (Figure S1A), with its expression rapidly extinguished upon

thymic maturation (Narayan et al., 2012). Thus, all alterations in ILTCs associated with the absence of SOX13 must originate in the precursors or at the CD24<sup>hi</sup> stage. In *Sox13*<sup>-/-</sup> mice, the frequencies of CD44<sup>hi</sup> V2 cells were severely reduced in peripheral tissues, and CD24<sup>lo</sup> mature (mat) V2 thymocytes were diminished to ~50% of the WT (Figures 1A, S1B and S1C). The numbers of other effectors were only marginally lower (Figure S1C and data not shown). Critically, the V2 cells that were specifically absent in *Sox13*<sup>-/-</sup> mice were ROR t<sup>+</sup>CCR6<sup>+</sup>CD27<sup>-</sup>CD44<sup>hi</sup>CD62L<sup>-</sup> T 17 cells (Narayan et al., 2012). Fetal and adult ROR t<sup>+</sup> matV2 thymocytes, the immediate precursors of peripheral T 17 cells, were missing (Figures 1B and S1D), while the number of immV2 cells was not significantly altered. The remaining V2 cells in *Sox13*<sup>-/-</sup> mice did not synthesize IL-17 (or IL-17F, data not shown) *ex vivo* (Figure 1B), even after stimulation with the TLR2 ligand, Zymosan (Figure 1C). These results demonstrate that the high SOX13 expression in developing immV2 thymocytes is a critical factor in T 17 cell differentiation.

The loss of V2 T 17 cells occurred in both fetal and adult *Sox13*<sup>-/-</sup> thymus. Fetal-derived V 4<sup>+</sup> (V4) T cells are the alternate IL-17 producers (Shibata et al., 2008). V 4 gene rearrangements, which predominate in early fetal stages, precede that of V 2 and the fetal V 4 chain is paired with the germline encoded V 1TCR. While V4 T 17 cells were negatively impacted in the fetal thymus by the absence of SOX13, these effectors were present in neonatal and adult *Sox13*<sup>-/-</sup> mice (Figures S1E, S1F and S1G). This result suggests that despite the lineage and functional relatedness (Narayan et al., 2012), developmental requirements for V2 and V4 T 17 cells are distinct.

B lymphocyte kinase (BLK) is essential for T 17 development (Laird et al., 2010). Ectopic Sox13 expression induces Blk expression in thymocytes (Melichar et al., 2007) and T cells, BLK<sup>+</sup> cells are the sole source of IL-17 during pathogen challenge (Laird et al., 2010; Narayan et al., 2012). In Sox13<sup>-/-</sup> mice, V2 T 17 precursors (immV2 cells) expressing normal amounts of BLK were depleted and the BLK and ROR t co-expressors were specifically absent (Figure 1D). Analysis of RorcGfp/+:Sox13-/- mice showed decreased, but still significant, transcription of *Rorc* in the mutant immV2 cells (Figure 1E). These results suggested that SOX13-regulated BLK expression at the immature stage is critical for T 17 cell differentiation. In support of this interpretation, transgenic (Tg) expression of Sox13 in all developing cells (Melichar et al., 2007) increased the proportions of BLK<sup>+</sup> TCR<sup>+</sup> cells, as well as the amount of BLK expression per cell, independent of TCR repertoire (Figure 1F). Correspondingly, more T cells in peripheral tissues produced IL-17 (Figure 1G). This enhancement was pronounced for V4 (V 2<sup>-</sup>), while high ectopic Sox13 expression was particularly detrimental for the survival of V2 cells that express the highest endogenous amount of Sox13 (Melichar et al., 2007), confounding their analysis in the gain-of-function model system. The absence of V2 T 17 cells in Sox13<sup>-/-</sup> mice, and the increased IL-17 production from T cells by the ectopic expression of SOX13 indicate that SOX13 is necessary for programming IL-17 production in ILTCs.

# Sox4 regulates RORyt expression and is necessary for IL-17-mediated skin inflammation

Thymic precursors lacking SOX4 also did not generate V2 T 17 ILTCs in vivo (Figure 2). SOX4 is expressed highly in T and B cell precursors as well as in immature CD4<sup>+</sup>CD8<sup>+</sup> double positive (DP) and thymocyte subsets (Immgen.org). SOX4 is a transcriptional activator and was shown to also physically interact with TCF1 and LEF1 ((Sinner et al., 2007) and data not shown). We generated T cell specific *Sox4*-deficient (T-*Sox4*-/-) mice to evaluate SOX4's function in ILTCs by breeding CD2 promoter driven Cre (CD2p-Cre) transgenic (Tg) mice to *Sox4*<sup>fl/fl</sup> mice (Penzo-Mendez et al., 2007). Mature adaptive thymocytes were generated in T-*Sox4*-/- mice. Strikingly, V2 T 17 ILTCs were not observed in T-*Sox4*-/- mice, while other effector subsets were present (Figure 2A and

data not shown). As in  $Sox13^{-/-}$  mice the V2 cells that were completely lost in peripheral lymphoid tissues were ROR t+CCR6+CD27-CD44hiCD62L-T 17 cells (Figure 2A and 2B). ROR t+CCR6+CD27lo matV2 thymocytes were virtually undetectable in fetal and adult T- $Sox4^{-/-}$  mice (Figure 2A and data not shown), while immV2 cells were present in normal proportions (Figure S2A) and did not exhibit decreased rates of survival or proliferation (Figure S2B). Accordingly, the remaining differentiated V2 cells in T- $Sox4^{-/-}$  mice did not produce IL-17 *ex vivo* (Figure 2A). The block in T 17 cells correlated with a loss of *Rorc* transcription (based on  $Rorc^{Gfp/+}$ :T- $Sox4^{-/-}$  mice) and ROR t protein expression beginning in immV2 thymocytes (Figures 2B and S2C). This loss was nearly absolute, more severe than the decrease observed in  $Sox13^{-/-}$  mice (Figure 1E). In contrast, ROR t expression in DP thymocytes was unaffected by the loss of SOX4 (Figure 2C), indicating that SOX4 is

a ILTC-specific modulator of ROR t expression.

T 17 cells have been implicated in the dermal inflammation-driven psoriasis-like disease in mice (Cai et al., 2011; Pantelyushin et al. 2012). The disease can be induced by the application of the TLR7 ligand Imiquimod (IMQ) to skin. T 17 cells residing in the dermis have been shown to be the primary lymphoid responders responsible for the disease. To determine whether SOX4 is necessary to generate pathogenic dermal T 17 cells, we first assessed the distribution of T cell subsets in the dermis of T-Sox4—mice. V2, but not V4, T 17 cells were greatly reduced in T-Sox4—dermal tissues before treatment (Figures S2D and S2E). After topical application of IMQ for five days we observed significant thickening, scaling and erythema in WT mice. However, T-Sox4—mice did not show overt inflammation (Figures S2F and S2G), which was quantified by the adapted Psoriasis Area and Severity Index (PASI) scoring system (Figure 2D). The lack of inflammation was correlated with significantly decreased proportions of V2 T 17 cells (Figures S2D and S2E) and CD11b+Gr-1+ Neutrophils (Figure S2H) in the treated T-Sox4—dermis.

Unlike the dermis, V2 T 17 cells were a minor population relative to V 1<sup>+</sup>IL-17<sup>+</sup> V4 cells in skin draining LNs of resting WT mice (Figures S2I and S2J). V 1+IL-17+ V4 cells were decreased in number in the fetal T-Sox4-/- thymus (~30% of the WT number), and reduced but substantial numbers of these fetal-derived effectors were found in adult T-Sox4<sup>-/-</sup> thymus and lymph nodes (LNs, Figure S2I and data not shown). V4 LN T cells responded to IMQ, as indicated by an increase in the proportion of IL-17 producers (Figure S2I). However, this response, and the persistence of dermal V4 cells in T-Sox4<sup>-/-</sup> mice (Figures S2D and S2E), was insufficient to precipitate the fulminant inflammatory condition in the skin. In conjunction with previously published reports (Cai et al., 2012; Pantelyushin et al. 2012), these results indicate that SOX4-dependent V2 T 17 cells are the primary ILTCs mediating IMQ-mediated skin inflammation. In addition, the results showed that fetalderived V4 T 17 cells, while acutely dependent on SOX13 during gestation, have compensatory mechanisms to bypass the SOX4 requirement and replenish their numbers in peripheral tissues in the absence of either TFs. In contrast, the "late" V2 T 17 cells are not produced in the absence of Sox4 or Sox13, reinforcing the conclusion that these two ILTC subsets are generated under distinct conditions and are not functionally interchangeable.

## TCF1 restrains IL-17+ cell generation

*Tcf7* is turned on by Notch signaling to specify the T cell fate (Germar et al., 2011; Weber et al., 2011). Notch signaling also controls GALT ILC differentiation (Lee et al., 2012; Possot et al., 2011), raising the possibility that TCF1 is the core regulator of innate effector differentiation. In the absence of TCF1, development of thymic precursors and T cells is aberrant (Verbeek et al., 1995). While the total thymocyte number is not significantly decreased in young *Tcf7*—mice (Verbeek et al., 1995), we found that the effector programs of ILTCs were extensively distorted (Figures S3A and S3B). In particular, thymic and peripheral V2 cells exhibited skewed ratios of CCR6+ (marking T 17 cells) to CD27+

(IFN producers, (Ribot et al., 2009)) populations, with the latter subset being undetectable in some *Tcf7*<sup>-/-</sup> mice (Figure 3A). More than 80% of *Tcf7*<sup>-/-</sup> V2 cells produced IL-17, twice the frequency observed in WT V2 cells, and they were uniformly ROR t<sup>+</sup> (Figure 3A). The bias towards IL-17 production was not V2 cell-specific as the number of thymic mature V 1.1<sup>+</sup> (normally IFN <sup>+</sup>) cells expressing IL-17 was also increased by >10 fold (Figure S3C). This pattern was not observed in *Tcrb*<sup>-/-</sup> mice (N.M., unpublished), indicating that the deregulated effector programming is not simply a consequence of the decreased production of thymocytes in *Tcf7*<sup>-/-</sup> mice.

In all thymic subtypes, the decreased expression of CD27 was already evident at the immature stage (Figure 3B). This pattern, along with a relatively normal cell cycle status of thymocytes (Figure S3D), suggested that the proclivity of TCF1-deficient ILTCs towards the IL-17 effector fate is an early developmental event, not a consequence of altered maintenance of mature effectors. This interpretation was further supported by the LEF1 expression pattern. LEF1 was a discriminatory regulator of effectors, as evidenced by its mutually exclusive expression to ROR t in thymocytes (Figures 3C and S3E) and the partial and complete loss of LEF1<sup>+</sup> subsets in V 1.1<sup>+</sup> and V2 cells, respectively, when TCF1 was absent (Figures 3C and 3D), again starting at the immature stage of differentiation (Fig. 3D). Lef1 expression is primarily controlled by TCF1 (Driskell et al., 2007). Given the precedent that some TCF1 target gene expression can be inhibited by SOX13 (Marfil et al., 2010; Melichar et al., 2007), high amounts of SOX13 in immV2 thymocytes may interfere with TCF1-mediated induction of Lef1. Consistent with this, immature TCR<sup>+</sup> thymocytes from Sox13Tg mice expressed significantly lower amounts of LEF1 and CD27 (Figure S3F). Taken together, TCF1 is necessary for pan- T cell development (Figures S3G and S3H) and it programs T effector subset differentiation, promoting and inhibiting IFN and IL-17 production, respectively, whereas SOX4 and SOX13 have the opposite function.

## **HMG TF chromatin occupancy**

Fetal and adult immV2 thymocytes share the TF transcriptome (Figures S4A and S4B). To determine whether HMG TFs directly regulate the T 17 gene network, we examined their chromatin occupancies at three gene loci (Blk, Rorc and II17a) that are the hallmarks of T 17 cells, along with the ubiquitously active Gata3 locus as a control, in ex vivo immature V 2<sup>+</sup> and V 2<sup>-</sup> thymocytes. First, we established epigenetic chromatin modifications of the gene loci. For comparison, in vitro differentiated adaptive Th1 and Th17 examined. Among T cell subsets, *Blk* and *Rorc* are most abundantly expressed in V2 cells (Narayan et al., 2012). Accordingly, the Blk and Rorc loci were selectively enriched for active H3K4me3 (and acetylated H3, data not shown) modifications in immV 2<sup>+</sup> cells. Conversely, the Rorc locus was repressed in immV 2<sup>-</sup> cells as indicated by H3K27me3 markings (Figure S4C). In contrast, II17a was decorated exclusively with repressive H3K27me3 chromatin marks in the immature thymocytes, consistent with its restricted expression in mature thymocytes (Narayan et al., 2012). These results indicate that the distinct effector gene expression profiles of immature cell subsets are foremost regulated at the chromatin level.

Next, we determined HMG TF occupancy of *Blk*, *Rorc* and *II17a* loci. SOX13 was localized to the *Blk* and *Rorc* loci in immature V 2<sup>+</sup>, but not V 2<sup>-</sup>, thymocytes (Figure 4). The low signals in V 2– thymocytes can be accounted for by low SOX13 protein expression in the cells (Figure S1A). While SOX4 was detected at all four loci assessed in thymocytes, only the docking at the *Rorc* loci was conserved in Th17 cells. Moreover, SOX4 was particularly enriched at the Region 2 (R2) near the transcription start site dedicated for ROR t production in V 2<sup>+</sup> thymocytes (Ruan et al., 2011). These results supported the

above finding (Figure 2) that SOX4 is an essential regulator of *Rorc* expression in T 17 cells.

TCF1 was enriched at the *Blk* and *Rorc* loci in immature V 2<sup>+</sup> cells, but not in immature V 2<sup>-</sup> cells. TCF1 and LEF1 occupancy at the *II17a* locus exhibited distinct modality with TCF1 preferentially enriched at the intronic R2, previously shown to be a docking region in

T cells (Yu et al., 2011), in both thymic subsets and LEF1 at the promoter upstream R1, particularly in immature V  $2^-$  thymocytes. Consistent with the TCF1 chromatin occupancy in precursor cells (Weber et al., 2011), TCF1 was found docked onto the Gata3 locus in thymocyte subsets, but LEF1 was not. LEF1 was associated with the Blk locus in V  $2^+$  thymocytes, presumably in the ROR  $t^-$  fraction, based on the mutually exclusive expression of ROR  $t^-$  thymocytes (Figure 3C). That LEF1 docking at the  $t^-$  locus is neutral to suppressive for transcription is supported by a selective enrichment at the locus in

Th17 cells that do not express Blk. As expected, LEF1 was excluded from the Rorc locus in V  $2^+$  thymocytes. Integrated with the results from the genetic studies, these results indicate that the HMG TFs are direct transcriptional regulators of the T 17 genes. SOX13 and SOX4 cooperatively orchestrate T 17 differentiation by primarily controlling Blk and Rorc transcription, respectively. TCF1, implicated as a negative regulator of T 17 cells, was associated with all the loci examined. Its docking at the Rorc and Blk loci was V  $2^+$  cell type-specific, a pattern overlapping with SOX13 and SOX4, and raises the likelihood that a combinatorial assortment of HMG TFs at each target gene locus is directly controlling ILTC effector fate specification.

# Conventional TCR signaling alone cannot specify Tγδ17 fate

A potential mechanistic explanation for the distinct global gene expression profiles of effector subsets is that different TCR chains (for example, V 1.1/V 5 versus V 2/V 4) convey different signals to establish diverse differentiation programs. For extrathymic adaptive Th17 cell differentiation, TCR signaling-induced IRF4 (Brustle et al., 2007) and ITK-NFAT (Gomez-Rodriguez et al., 2009) are critical regulators of Rorc and II17a expression, respectively. IRF4 is dispensable for T 17 cell differentiation (Powolny-Budnicka et al., 2011). The role of ITK in T 17 differentiation was unknown. Peripheral T cells were impaired in their  $Ca^{2+}$  response when they were activated via TCR stimulation in vitro (Figure S5A), establishing ITK as a key signal integrator of TCR signaling. In the absence of ITK, the transcriptomes of immV2 thymocytes converged with cell subsets, as indicated by principal component analysis (PCA, Figure 5A) that clusters related populations based on the major components of gene expression variability. ITK signaling was responsible for ~90% of the unique immV2 thymocyte transcriptome (Figure S5B). However, the characteristic TF profile of immV2 cells was mostly insulated from change when ITK was absent, as shown by hierarchical clustering (Figure 5B), correlating with the relatively normal generation of T 17 cells in *Itk*—mice (Figure S5C). These results demonstrate that while V 2TCR-ITK signaling is central to the establishment of distinct transcriptomes of subsets it is not responsible for the wiring of subset-specific TF networks at the immature stage. Together, these results indicate that the conventional TCR signaling pathways so far implicated in adaptive Th17 differentiation do not dominantly specify the T 17 cell fate.

To directly assess the role of the TCR in T 17 cell differentiation, T effector development was tracked in V 2 TCR Tg mice where nearly all T cells express the identical V 2 TCR chain (Kang et al., 1998). V 2 TCR Tg expression on the cell surface is controlled by endogenous TCR chain gene rearrangement and expression. If the TCR is deterministic for effector fate, expression of a functional V 2<sup>+</sup> TCR in all T cells should enhance the generation of T 17 cells. The Tg mice, however, did not produce a significantly enhanced number of IL-17<sup>+</sup> cells, nor could the *Tcrg* Tg expression in

 $Sox13^{-/-}$  mice rescue the T 17 differentiation defect (Figure 5C). These results indicated that specific V 2 TCR signaling *per se* is not the dominant determinant of effector lineage specification.

If the TCR signaling alone cannot specify ILTC effector fates, an alternate possibility was that distinct effector programs are pre-set at different developmental stages. To test whether T cell developmental intermediates possess unique effector generative capacity we compared the ability of the early c-Kit (CD117)<sup>+</sup> T progenitors (ETP) versus the late c-Kit<sup>neg</sup> DN3 precursors to generate T 17 effectors. ETPs (fetal and adult) generated CCR6<sup>+</sup>CD27<sup>-</sup> T 17 V2 cells in the standard OP9-DL1 culture system (Figure 5D). However, no significant generation of CCR6<sup>+</sup>CD27<sup>-</sup> V2 cells was detectable from DN3 precursors. Further, the late precursors were markedly biased to produce V1 and V2 CD27<sup>+</sup> cells (Figure S5D and data not shown). Together, these findings suggest that the maturational state of the precursors, and not TCR signaling alone, is a key determinant of T 17 effector lineage specification.

## TCF1 is necessary for GALT ILC differentiation

One implication of the dominance of the HMG TF network in ILTC effector differentiation was that a similar regulatory gene network may operate to generate GALT ILCs that lack clonal antigen receptors. GALT ILCs express several HMG TFs at the mRNA level. These include Tcf7, Sox4 and Tox (Aliahmad et al., 2010), though not Sox13 ((Reynders et al., 2011) and data not shown). To determine if HMG TF networks control innate effector differentiation extrathymically we first established the ILC subset-specific expression pattern of TCF1 and LEF1 proteins and Axin2, a canonical TCF1-WNT signaling target that can serve as a reporter of TCF1 as a transcriptional activator (Lustig et al., 2002). In mLN and splenic CD3<sup>-</sup>CD19<sup>-</sup> cells, TCF1 was expressed highly in IL-7R<sup>+</sup> subsets, with all IL-7RhiROR t+ LTi-like ILCs uniformly positive. The majority of mLN IL-7R+NKp46+ NCR22 cells also expressed TCF1 (Figures 6A, 6B and S6A), whereas <10% of the ROR t<sup>-</sup>IL-7R<sup>-</sup> was TCF1<sup>+</sup>. Expression of TCF1 and CD4, a classic marker of LTi cells, was mostly concordant, with only some CD4<sup>+</sup>IL-<sup>7</sup>R<sup>lo-neg</sup> cells lacking TCF1. LEF1, coexpressed with TCF1 in adaptive T cells, was not expressed in LTi-like or NCR22 ILCs (Figure 6A), paralleling its exclusion from thymocytes fated for IL-17 production (Figure 3C). Similar results were obtained with neonatal intestinal Lamina Propria (LP) ILC subsets (data not shown). Axin2 was variably expressed in TCF1+ ILC subsets, with LTi-like ILCs (c-Kit<sup>+</sup>IL-7R<sup>+</sup>Lin<sup>-</sup>, 4 7<sup>+/-</sup>, >50% Axin2<sup>+</sup>) considerably enriched for WNT signaling activity than in NCR22 ILCs (~10% Axin2+) (Figure S6B). These results indicate that while TCF1 is expressed in most, but not all ILCs, it is likely to have broad activities beyond that of the canonical WNT signaling transcriptional activator.

To determine the range of TCF1 function, ILC subset composition and function in the small intestine, mLN and spleen of  $Tcf7^{-/-}$  mice were examined. In  $Tcf7^{-/-}$  neonatal intestines and spleens, NKp46<sup>+</sup>IL-7R<sup>+</sup> NCR22 ILCs were specifically absent, whereas CD4<sup>+</sup> LTi-like ILCs were over-represented proportionally, but only marginally increased in numbers (Figure 6C and data not shown). LTi-like ILCs are CCR6<sup>+</sup>CD25<sup>+</sup> (Sawa et al., 2010; Vonarbourg et al., 2010) and the frequency of the CCR6<sup>+</sup> fraction was elevated, a trend that was already evident in  $Tcf7^{+/-}$  heterozygotes (Figure 6D). However,  $Tcf7^{-/-}$  LTi-like ILCs lost CD25 expression, most likely indicating that as in T cell precursors (Weber et al., 2011), TCF1 may be a positive regulator of Cd25 transcription in ILCs.

In 3–4 week old *Tcf7*<sup>-/-</sup> mice, the number of ROR t<sup>+</sup> ILCs was reduced to one third of normal in the mLN, while IL-7R<sup>+</sup>CD3<sup>-</sup>CD19<sup>-</sup>ROR t<sup>neg-lo</sup> fraction was decreased by 10 fold (Figure 6E). As in neonates, NKp46<sup>+</sup> ILCs were specifically depleted (Figures 6E, 6F, and S6C). These results show that TCF1 is absolutely required for NCR22 cell generation,

whereas LTi-like ILC production *per se* appears less dependent on TCF1. During T 17 differentiation, TCF1 dampened effector capacity (Figure 3). To determine whether TCF1 functions similarly in differentiated ILCs, the effector capacity of *Tcf7*<sup>-/-</sup> ILCs was assessed. All ROR t<sup>+</sup> ILCs in *Tcf7*<sup>-/-</sup> mice expressed higher amounts of ROR t/cell (Figure 6G) and were capable of enhanced IL-17 production (Figure 6H, top row). Upon activation with TLR2 agonist Zymosan, IL-17 and IL-22 production from *Tcf7*<sup>-/-</sup> LTi-like ILCs was significantly elevated (Figures 6H and S6C). Thus, as in ILTC development, TCF1 has a dual function in ILC development, coordinating normal gene induction to ensure proper differentiation of ILC subsets and controlling effector function by restraining ROR t expression and IL-17/22 production.

## **Discussion**

We showed that dermal SOX13 and SOX4-dependent V2 T 17 cells are the primary innate lymphoid mediators of psoriasis-like disease in C57BL/6 mice and they develop in the thymus under the control of a HMG TF regulatory network. Adaptive Th17 cell differentiation in peripheral tissues requires TCR signaling and its downstream targets ITK (Gomez-Rodriguez et al., 2009) and IRF4 (Brustle et al., 2007), the inflammatory cytokine IL-6 and its signal mediator STAT3 (Zhou et al., 2007) as well as TGF activated SMAD2 (Malhotra et al., 2010). None of these factors are essential for T 17 ILTC development in the thymus (Lochner et al., 2008; Malhotra et al., 2010; Powolny-Budnicka et al., 2011). Instead, a complex network of HMG TFs cooperatively controls thymic ILTC differentiation by direct regulation of key genes involved in effector function. Among them, SOX4 and SOX13 are the central positive regulators of T 17 differentiation, by primarily inducing ROR t and BLK, respectively, and potentially localizing their interacting partner TCF1 to select chromatin sites. Given that HMG TFs operate in conjunction with co-factors, a detailed understanding of target gene-specific function of SOX4 and SOX13 awaits the full characterization of transcriptional complexes assembled by each factor.

During early fetal dendritic epidermal T cell (V 3<sup>+</sup>) differentiation, cell surface SKINT signaling normally suppresses *Rorc* and *Sox13* expression to block IL-17 production (Turchinovich and Hayday, 2011), underscoring the importance of SOX13 in positively enforcing IL-17 effector fate that must be circumvented to generate alternate innate effector cells in the fetuses. SOX13 regulates several key factors of V2 T 17 cell differentiation, including Blk, Rorc and Etv5 (K.S., unpublished). The exclusion of LEF1 from developing T 17 cells is also likely to be established by SOX13, as suggested by the diminished Lef1 expression in Sox13Tg mice. While published studies to date support protein-protein interactions as the main regulatory mode of SOX13-TCF1 functions, it remains possible that each can impact chromatin occupancy of the other. For instance, the loss of TCF1 may result in more precursors with SOX13 bound to the Rorc locus, thereby leading to the enhanced generation of T 17 cells. However, Tcf7<sup>-/-</sup> cells do not express LEF1, and the loss of LEF1-dependent effector developmental potential may also indirectly enhance T 17 cell production. A systemic approach that can simultaneously track all relevant HMG TFs during 17 differentiation from thymic precursors will be necessary to define the rules governing functional connectivities of HMG TFs.

The mechanism by which the temporally disparate emergence of effector subtypes is linked to specific TCR and repertoire remains to be determined. We have identified ITK as a discriminatory signal mediator of TCR that is required for the molecular divergence of V2 cells from other cell subsets. Previously, it has been shown that some IL-17 $^+$  V  $^+$  T cells can be generated in the absence of ligand recognition, whereas TCR triggering led to the capacity to produce IFN (Jensen et al., 2008). In vitro assays, however, showed that the cell surface expression of V 2TCR itself is uniquely able to trigger signaling, akin to the

preTCR signaling that generates DP cells. Given the substantial, but constrained, alterations of V2 cells in *Itk*<sup>-/-</sup> mice, we propose that the V 2TCR-ITK signaling constitutes a developmental checkpoint related to the -selection for thymocytes, but that this tonic signaling alone does not regulate the TF transcriptome that programs the T 17 effectors.

Published data (Jensen et al., 2008; Ribot et al., 2009; Turchinovich and Hayday, 2011) and our results from the in vitro cultures and TCR Tg mice indicate at least two other factors that can contribute to the observed correlation between TCR repertoire and effector function: developmental timing and limiting permissive niches. In the OP9 culture system DN3 cells and their progenies cannot generate T 17 cells, indicating a developmental stage-specific gene program, perhaps linked to an ordered *Tcrgv* gene rearrangement process. However, the enforced expression of V 2TCR does not enhance the number of T 17 cells generated in vivo, indicating that V 2TCR-specific signals alone cannot dictate effector fate and that there exists a limit to the number of T 17 cells that can be produced regardless of the TCR repertoire.

Recently, it has been concluded that most T 17 cells are generated during gestation (Haas et al., 2012). While this can account for the correlation for V4 cells, whether V2 T 17 cells also originate exclusively during gestation remains to be clarified. The requirements for SOX4 and SOX13 in the generation of V2 and V4 T 17 cells are distinct, with V2 T 17 cells showing an absolute dependence, while V4 T 17 cells are mostly dependent on SOX13, but even here only the fetal thymic cellularity was significantly impacted by the loss of *Sox13*. These distinct developmental requirements between V2 and V4 cells is observed despite their overall molecular similarity at the gene expression level (Narayan et al., 2012), suggesting T cell-extrinsic environmental signals differentially affecting the early (V 4+) versus late (V 2+) T 17 cell development.

The high Tcf7 expression is an unifying feature of developing thymocytes and GALT ILCs. Notch signaling has been shown to directly induce *Tcf7* transcription (Germar et al., 2011; Weber et al., 2011). Based on the known targets of TCF1 in T cells and their precursors, TCF1 may directly regulate the expression of several markers of GALT ILCs, including *Id2* (Germar et al., 2011; Rockman et al., 2001), *II7r* (Germar et al., 2011), *Cd4* (Huang et al., 2006) and Cd25 (Weber et al., 2011). For ILCs, Tcf7-deficiency led to the selective loss of NCR22 cells that have been shown to be most dependent on Notch signaling for development (Lee et al., 2012). Other ROR t<sup>+</sup> ILCs are mostly spared, although their functional profiles are altered when TCF1 is absent, as evidenced by the hyper production of cytokines, reminiscent of *Tcf7*<sup>-/-</sup> ILTCs. Thus, TCF1 is a negative regulator of IL-17 and IL-22 production in differentiated innate lymphoid effectors. An analogous (Yu et al., 2011) or distinct (Muranski et al., 2011) function of TCF1 in adaptive T cells has been proposed, but in vivo, TCF1 may primarily impact Th17 cell survival or renewal. This difference in the repertoire of TCF1 function in innate versus adaptive lymphocytes is likely linked to the dominance of TCR and cytokine receptor signaling in specifying adaptive effector differentiation, whereas the production of fast-acting innate lymphoid effectors is acutely dependent on intrinsic gene networks programmed in the tissues of origin. TCF1 may also be required for fetal LTi development as *Tcf7*<sup>-/-</sup> mice do not generate Peyer's patches (N.M. unpublished), similar to mice lacking the HMG TF Tox (Aliahmad et al., 2010). Together, these results suggest that the diversity of ROR t<sup>+</sup> innate lymphoid subsets can be generated by unique combinatorial usage of HMG TFs in precursors arising in distinct tissues.

## **EXPERIMENTAL PROCEDURE**

#### Mice

Sox13<sup>-/-</sup> (129/J), Sox13 Tg (Melichar et al., 2007), TcrVg2 Tg (C57BL/6) (Kang et al., 1998), Axin2<sup>lz/+</sup> (H. Birchmeier, MDC Berlin), Tcrb<sup>-/-</sup>, Rorc-Gfp (JAX), Itk<sup>-/-</sup> (Felices et al., 2009) and Tcf7<sup>-/-</sup> mice (Verbeek et al., 1995) were previously described. Sox4<sup>fl/fl</sup> mice were generated by V. Lefebvre (Penzo-Mendez et al., 2007) and crossed to CD2p-CreTg mice. All mice were housed in a specific pathogen free barrier facility and experiments performed were approved by the IACUC.

## Flow cytometry

Antibodies (Abs) used are detailed in Supplementary Information. Data was acquired on a BD LSRII cytometer and was analyzed using FlowJo (Treestar).

# Ex vivo stimulation, Zymosan activation and OP9 culture

Freshly isolated thymic and LN cells were cultured (2×10<sup>6</sup>/well) with PMA (10ng/ml) and Ionomycin (1µg/ml) for 4 hrs at 37°C, with Golgi Stop and Golgi Plug (BD Biosciences) added after 1 hr. After stimulation, cells were stained for cell surface markers and intracellular cytokine production using the Cytofix/Cytoperm kit (BD Biosciences). To activate innate effectors, mice were injected intra-peritoneally with Zymosan (Sigma) in PBS (6mg/mouse). Four hrs post-injection, lymphocytes were isolated from the mLN and spleens. Cells were stimulated with PMA/Iono and intracellular staining for IL-22 and IL-17 in ILTCs and ILCs was performed. Intestinal LP lymphocytes from 10 day old mice was isolated as described (Qiu et al., 2012). Sorted fetal and adult ETPs (c-Kit+CD4-CD8-CD3-CD25-CD44+) or c-Kit-DN3 (CD4-CD8-CD3-CD25+CD44-) cells were plated onto OP9-DL1 monolayers (J. C. Zuniga-Pflucker) at varous concentrations in MEM media containing 20% FBS (Gibco), 1ng/ml IL-7 (R&D Systems) and 5ng/ml Flt3L (R&D Systems). After 5–12 days of culture, cells were analyzed by flow cytometry.

## **Psoriasis induction**

Aldara (5% Imiquimod, 3M Pharmaceuticals) or control vehicle cream was applied daily for five days on the back and ear. The disease severity in mice was scored by a modified PASI normally used to rank human psoriasis severity (Fredriksson and Pettersson, 1978). The scale thickness and erythema were scored from 0–4 (slight, moderate, severe, very severe), and the total area of the inflammation covering the back was scored from 0–6 (0%, 10–29%, 30–49%, 50–69%, 70–89%, 90–100%). The scores for the scales and erythema were added and multiplied by the score for the body area to obtain the total score ranging from 0 (No disease) to 48. Dermal cells were obtained according to a published protocol (Suffia et al., 2005).

## Microarray analysis

Samples were processed and analyzed according to the standard operating protocol of the Immunological Genome Project (Immgen.org and Supplemental Information). GEO:GSE15907.

# Chromatin immunoprecipitation (ChIP) assay

Sorted immature V  $2^+$  and V  $2^-$  thymocyte subsets were used to determine HMG TF chromatin occupancy at the *Blk*, *Rorc*, *II17a* and *Gata3* loci using commercially available Abs, reagents and kits. In vitro differentiated Th1 and Th17 cells were used as controls. Detailed method is provided in Supplemental Information.

# **Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

# **Acknowledgments**

We thank M. Bix and E. Huseby for comments on the manuscript, the ImmGen core team (M. Painter, J. Ericson, S. Davis) for help with data generation and processing, eBioscience, Affymetrix, and Expression Analysis for support of the ImmGen Project, and H. Birchmeier and H. Clevers for mice. Supported by NIH/NCI CA100382 to J.K., NIH/NIAID AI084987 to L.J.B., AI072073 to ImmGen and NIH/NIAMS AR54153 to V.L.

#### References

- Aliahmad P, de la Torre B, Kaye J. Shared dependence on the DNA-binding factor TOX for the development of lymphoid tissue-inducer cell and NK cell lineages. Nat Immunol. 2010; 11:945–952. [PubMed: 20818394]
- Badis G, Berger MF, Philippakis AA, Talukder S, Gehrke AR, Jaeger SA, Chan ET, Metzler G, Vedenko A, Chen X, et al. Diversity and complexity in DNA recognition by transcription factors. Science. 2009; 324:1720–1723. [PubMed: 19443739]
- Brustle A, Heink S, Huber M, Rosenplanter C, Stadelmann C, Yu P, Arpaia E, Mak TW, Kamradt T, Lohoff M. The development of inflammatory Th17 cells requires interferon-regulatory factor 4. Nat Immunol. 2007; 8:958–966. [PubMed: 17676043]
- Buonocore S, Ahern PP, Uhlig HH, Ivanov II, Littman DR, Maloy KJ, Powrie F. Innate lymphoid cells drive IL-23-dependent innate intestinal pathology. Nature. 2010; 464:1371–1375. [PubMed: 20393462]
- Cai Y, Shen X, Ding C, Qi C, Li K, Li X, Jala VR, Zhang HG, Wang T, Zheng J, Yan J. Pivotal role of dermal IL-17-producing T cells in skin inflammation. Immunity. 2011; 35:596–610. [PubMed: 21982596]
- Driskell RR, Goodheart M, Neff T, Liu X, Luo M, Moothart C, Sigmund CD, Hosokawa R, Chai Y, Engelhardt JF. Wnt3a regulates Lef-1 expression during airway submucosal gland morphogenesis. Dev Biol. 2007; 305:90–102. [PubMed: 17335794]
- Felices M, Yin CC, Kosaka Y, Kang J, Berg LJ. Tec kinase Itk in T cells is pivotal for controlling IgE production in vivo. Proc Natl Acad Sci U S A. 2009; 106:8308–8313. [PubMed: 19416854]
- Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978; 157:238–244. [PubMed: 357213]
- Germar K, Dose M, Konstantinou T, Zhang J, Wang H, Lobry C, Arnett KL, Blacklow SC, Aifantis I, Aster JC, Gounari F. TCF-1 is a gatekeeper for T-cell specification in response to Notch signaling. Proc Natl Acad Sci U S A. 2011; 108:20060–20065. [PubMed: 22109558]
- Gomez-Rodriguez J, Sahu N, Handon R, Davidson TS, Anderson SM, Kirby MR, August A, Schwartzberg PL. Differential expression of IL-17A and -17F is coupled to TCR signaling via inducible T cell kinase. Immunity. 2009; 31:587–597. [PubMed: 19818650]
- Haas JD, Ravens S, Duber S, Sandrock I, Oberdorfer L, Kashani E, Chennupati V, Fohse L, Naumann R, Weiss S, et al. Development of IL-17-Producing T Cells Is Restricted to a Functional Embryonic Wave. Immunity. 2012
- Huang Z, Xie H, Ioannidis V, Held W, Clevers H, Sadim MS, Sun Z. Transcriptional regulation of CD4 gene expression by TCF-1/ -catenin pathway. J Immunol. 2006; 176:4880–4887. [PubMed: 16585583]
- Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR. The orphan nuclear receptor ROR t directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006; 126:1121–1133. [PubMed: 16990136]
- Jensen KD, Su X, Shin S, Li L, Youssef S, Yamasaki S, Steinman L, Saito T, Locksley RM, Davis MM, et al. Thymic selection determines T cell effector fate: antigen-naive cells make IL-17 and antigen-experienced cells make IFN. Immunity. 2008; 29:90–100. [PubMed: 18585064]
- Kang J, Coles M, Cado D, Raulet DH. The developmental fate of T cells is critically influenced by TCR expression. Immunity. 1998; 8:427–438. [PubMed: 9586633]

Laird RM, Laky K, Hayes SM. Unexpected role for the B cell-specific Src family kinase BLK in the development of IL-17-producing T cells. J Immunol. 2010; 185:6518–6527. [PubMed: 20974990]

- Lee JS, Cella M, McDonald KG, Garlanda C, Kennedy GD, Nukaya M, Mantovani A, Kopan R, Bradfield CA, Newberry RD, Colonna M. AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch. Nat Immunol. 2012; 13:144–151. [PubMed: 22101730]
- Lochner M, Peduto L, Cherrier M, Sawa S, Langa F, Varona R, Riethmacher D, Si-Tahar M, Di Santo JP, Eberl G. In vivo equilibrium of proinflammatory IL-17+ and regulatory IL-10+ Foxp3+ ROR t + T cells. J Exp Med. 2008; 205:1381–1393. [PubMed: 18504307]
- Luci C, Reynders A, Ivanov II, Cognet C, Chiche L, Chasson L, Hardwigsen J, Anguiano E, Banchereau J, Chaussabel D, et al. Influence of the transcription factor ROR t on the development of NKp46+ cell populations in gut and skin. Nat Immunol. 2009; 10:75–82. [PubMed: 19029904]
- Lustig B, Jerchow B, Sachs M, Weiler S, Pietsch T, Karsten U, van de Wetering M, Clevers H, Schlag PM, Birchmeier W, Behrens J. Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol Cell Biol. 2002; 22:1184–1193. [PubMed: 11809809]
- Malhotra N, Robertson E, Kang J. SMAD2 is essential for TGF beta-mediated Th17 cell generation. J Biol Chem. 2010; 285:29044–29048. [PubMed: 20656683]
- Marfil V, Moya M, Pierreux CE, Castell JV, Lemaigre FP, Real FX, Bort R. Interaction between Hhex and SOX13 modulates Wnt/TCF activity. J Biol Chem. 2010; 285:5726–5737. [PubMed: 20028982]
- Melichar HJ, Narayan K, Der SD, Hiraoka Y, Gardiol N, Jeannet G, Held W, Chambers CA, Kang J. Regulation of versus T lymphocyte differentiation by the transcription factor SOX13. Science. 2007; 315:230–233. [PubMed: 17218525]
- Muranski P, Borman ZA, Kerkar SP, Klebanoff CA, Ji Y, Sanchez-Perez L, Sukumar M, Reger RN, Yu Z, Kern SJ, et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity. 2011; 35:972–985. [PubMed: 22177921]
- Narayan K, Sylvia KE, Malhotra N, Yin CC, Martens G, Vallerskog T, Kornfeld H, Xiong N, Cohen NR, Brenner MB, et al. Intrathymic programming of effector fates in three molecularly distinct T cell subtypes. Nat Immunol. 2012; 13:511–518. [PubMed: 22473038]
- O'Brien RL, Roark CL, Born WK. IL-17-producing T cells. Eur J Immunol. 2009; 39:662–666. [PubMed: 19283718]
- Pantelyushin S, Haak S, Ingold B, Kulig P, Heppner FL, Navarini AA, Becher B. Ror t+ innate lymphocytes and T cells initiate psoriasiform plaque formation in mice. J Clin Invest. 2012; 122:2252–2256. [PubMed: 22546855]
- Penzo-Mendez A, Dy P, Pallavi B, Lefebvre V. Generation of mice harboring a Sox4 conditional null allele. Genesis. 2007; 45:776–780. [PubMed: 18064674]
- Possot C, Schmutz S, Chea S, Boucontet L, Louise A, Cumano A, Golub R. Notch signaling is necessary for adult, but not fetal, development of ROR t(+) innate lymphoid cells. Nat Immunol. 2011; 12:949–958. [PubMed: 21909092]
- Powolny-Budnicka I, Riemann M, Tanzer S, Schmid RM, Hehlgans T, Weih F. RelA and RelB transcription factors in distinct thymocyte populations control lymphotoxin-dependent IL-17 production in T cells. Immunity. 2011; 34:364–374. [PubMed: 21419662]
- Qiu J, Heller JJ, Guo X, Chen ZM, Fish K, Fu YX, Zhou L. The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity. 2012; 36:92–104. [PubMed: 22177117]
- Rachitskaya AV, Hansen AM, Horai R, Li Z, Villasmil R, Luger D, Nussenblatt RB, Caspi RR. Cutting edge: NKT cells constitutively express IL-23 receptor and ROR t and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. J Immunol. 2008; 180:5167–5171. [PubMed: 18390697]
- Reynders A, Yessaad N, Vu Manh TP, Dalod M, Fenis A, Aubry C, Nikitas G, Escaliere B, Renauld JC, Dussurget O, et al. Identity, regulation and in vivo function of gut NKp46+ROR t+ and NKp46+ROR t- lymphoid cells. Embo J. 2011; 30:2934–2947. [PubMed: 21685873]

Ribot JC, deBarros A, Pang DJ, Neves JF, Peperzak V, Roberts SJ, Girardi M, Borst J, Hayday AC, Pennington DJ, Silva-Santos B. CD27 is a thymic determinant of the balance between iIFN - and IL-17-producing T cell subsets. Nat Immunol. 2009; 10:427–436. [PubMed: 19270712]

- Rockman SP, Currie SA, Ciavarella M, Vincan E, Dow C, Thomas RJ, Phillips WA. Id2 is a target of the -catenin/TCF pathway in colon carcinoma. J Biol Chem. 2001; 276:45113–45119. [PubMed: 11572874]
- Ruan Q, Kameswaran V, Zhang Y, Zheng S, Sun J, Wang J, DeVirgiliis J, Liou HC, Beg AA, Chen YH. The Th17 immune response is controlled by the Rel-ROR -ROR t transcriptional axis. J Exp Med. 2011; 208:2321–2333. [PubMed: 22006976]
- Sanos SL, Bui VL, Mortha A, Oberle K, Heners C, Johner C, Diefenbach A. RORgammat and commensal microflora are required for the differentiation of mucosal IL- 22-producing NKp46+ cells. Nat Immunol. 2009; 10:83–91. [PubMed: 19029903]
- Satoh-Takayama N, Vosshenrich CA, Lesjean-Pottier S, Sawa S, Lochner M, Rattis F, Mention JJ, Thiam K, Cerf-Bensussan N, Mandelboim O, et al. Microbial flora drives IL-22 production in intestinal NKp46+ cells that provide innate mucosal immune defense. Immunity. 2008; 29:958– 970. [PubMed: 19084435]
- Sawa S, Cherrier M, Lochner M, Satoh-Takayama N, Fehling HJ, Langa F, Di Santo JP, Eberl G. Lineage relationship analysis of ROR t+ ILCs. Science. 2010; 330:665–669. [PubMed: 20929731]
- Schilham MW, Moerer P, Cumano A, Clevers HC. Sox4 facilitates thymocyte differentiation. Eur J Immunol. 1997; 27:1292–1295. [PubMed: 9174623]
- Shibata K, Yamada H, Nakamura R, Sun X, Itsumi M, Yoshikai Y. Identification of CD25+ gamma delta T cells as fetal thymus-derived naturally occurring IL-17 producers. J Immunol. 2008; 181:5940–5947. [PubMed: 18941182]
- Sinner D, Kordich JJ, Spence JR, Opoka R, Rankin S, Lin SC, Jonatan D, Zorn AM, Wells JM. Sox17 and Sox4 differentially regulate -catenin/TCF activity and proliferation of colon carcinoma cells. Mol Cell Biol. 2007; 27:7802–7815. [PubMed: 17875931]
- Sonnenberg GF, Fouser LA, Artis D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol. 2011; 12:383–390. [PubMed: 21502992]
- Spits H, Di Santo JP. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat Immunol. 2011; 12:21–27. [PubMed: 21113163]
- Suffia I, Reckling SK, Salay G, Belkaid Y. A role for CD103 in the retention of CD4+CD25+ Treg and control of Leishmania major infection. J Immunol. 2005; 174:5444–5455. [PubMed: 15845457]
- Takatori H, Kanno Y, Watford WT, Tato CM, Weiss G, Ivanov II, Littman DR, O'Shea JJ. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med. 2009; 206:35–41. [PubMed: 19114665]
- Turchinovich G, Hayday AC. Skint-1 identifies a common molecular mechanism for the development of IFN -secreting versus IL-17-secreting T cells. Immunity. 2011; 35:59–68. [PubMed: 21737317]
- Verbeek S, Izon D, Hofhuis F, Robanus-Maandag E, te Riele H, van de Wetering M, Oosterwegel M, Wilson A, MacDonald HR, Clevers H. An HMG-box-containing T-cell factor required for thymocyte differentiation. Nature. 1995; 374:70–74. [PubMed: 7870176]
- Van Belle AB, de Heusch M, Lemaire MM, Hendrickx E, Warnier G, Dunussi-Joannopoulos K, Fouser LA, Renauld JC, Dumoutier L. IL-22 is required for IMQ-induced psoriasiform skin inflammation in mice. J Immunol. 2012; 188:462–469. [PubMed: 22131335]
- Vonarbourg C, Mortha A, Bui VL, Hernandez PP, Kiss EA, Hoyler T, Flach M, Bengsch B, Thimme R, Holscher C, et al. Regulated expression of nuclear receptor RORgammat confers distinct functional fates to NK cell receptor-expressing RORgammat(+) innate lymphocytes. Immunity. 2010; 33:736–751. [PubMed: 21093318]
- Weber BN, Chi AW, Chavez A, Yashiro-Ohtani Y, Yang Q, Shestova O, Bhandoola A. A critical role for TCF-1 in T-lineage specification and differentiation. Nature. 2011; 476:63–68. [PubMed: 21814277]
- Yu Q, Sharma A, Ghosh A, Sen JM. TCF-1 negatively regulates expression of IL-17 family of cytokines and protects mice from EAE. J Immunol. 2011; 186:3946–3952. [PubMed: 21339363]

Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, Levy DE, Leonard WJ, Littman DR. IL-6 programs Th17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007; 8:967–974. [PubMed: 17581537]

# **HIGHLIGHTS**

 SOX4, SOX13, LEF1 and TCF1 coordinately program innate IL-17 producing T cells

- SOX4 directly regulates ROR t induction
- TCR signaling components of adaptive IL-17<sup>+</sup> cells do not drive innate IL-17<sup>+</sup> cells
- TCF1 controls the production of innate IL-17 and IL-22 in the gut mucosa




Figure 1. SOX13 is essential for T 17generation

(A) Frequencies of activated and mature V 2<sup>+</sup> T cells in TCR<sup>+</sup> cells in the spleen and thymus, respectively, of WT and Sox13<sup>-/-</sup> mice. Representative data (numbers within the gates represent percents of total) from one experiment of at least four are shown. Similar results were obtained with T-Sox13<sup>-/-</sup>mice (B6). (B) The defects in T 17 generation originate in the thymus. LN and thymic mature (CD24<sup>lo</sup>) V 2<sup>+</sup> cells from WT and Sox13<sup>-/-</sup> mice were analyzed for the expression of ROR t and EOMES (an activator of Ifng transcription), cell surface CCR6 and CD27 and intracellular IL-17A and IFN in matV2 cells. Frequencies less than 0.5% are left as blanks. (C) Intracellular staining for IL-17 in splenic V2 cells isolated from mice 4 hr post Zymosan administration. (D) Left, Intracellular and nuclear staining for the two markers of T 17 cells, BLK and ROR t, in V2 thymocytes from neonatal mice at different maturational stages. Right, Staining of Abs to BLK and thymocytes was used as negative controls. (E) SOX13 partly regulates ROR t in CD4<sup>+</sup> ROR t expression in CD24hi immV2 thymocytes. A decrease in *Rorc* transcription (Top) as indicated by GFP expression from Rorc-Gfp substrate introduced to Sox13<sup>-/-</sup> mice, and intranuclear ROR t protein expression (Bottom). Representative data from one of two experiments is shown. (F) Intracellular staining for BLK in two maturation stages of V 2<sup>+</sup> thymocytes from LCKp-Sox13Tg mice. (G) Intracellular staining for IL-17A and V 2 in Sox13 Tg<sup>+</sup> LN T cells. See also Fig. S1.




Figure 2. SOX4 regulates ROR t expression during T 17 generation
(A) LN and mature thymic V 2<sup>+</sup> cells from WT (CD2p-Cre: Sox4<sup>+/+</sup>) and T-Sox4<sup>-/-</sup> mice were analyzed for the expression of ROR t, CCR6 and CD27 and intracellular IL-17 and IFN . Representative data from one of four experiments is shown. (B) SOX4 regulates ROR t expression in immV2 thymocytes. The loss of Rorc transcription (Top) as indicated by the loss of GFP expression from Rorc-Gfp substrate introduced to T-Sox4<sup>-/-</sup> mice, and intranuclear ROR t protein expression (Bottom). Representative data from one of three experiments is shown. (C) Overlayed histograms of ROR t staining in DP thymocytes in WT and T-Sox4<sup>-/-</sup> mice. The shaded histogram is the internal negative control for ROR t staining, gated on CD4<sup>+</sup> thymocytes that do not express Rorc. (D) PASI scoring was used to quantify the severity of psoriatic inflammation in IMQ treated mice. See also Fig.

S2. Data is represented as mean+/- SEM.




Figure 3. TCF1 constrains T 17generation

(A) Deregulated IL-17 production in *Tcf*7<sup>-/-</sup> mice. Differentiation of T 17 thymocytes was examined by analyses of ROR t and EOMES, CCR6 and CD27, and intracellular IL-17A and IFN expression in mature (CD24<sup>lo</sup>) V 1.1<sup>+</sup> and V 2<sup>+</sup> T cells. Similar results were obtained when peripheral T cell subsets were analyzed. Representative profiles from one of at least five independent experiments, each with minimum of three mice/genotype, are shown. (B) Expression of CD27 expression on *Tcf*7<sup>-/-</sup> immV2 thymocytes. A similar trend for increased ratio of CCR6/CD27 was observed with other thymic subtypes. (C) Left, Intranuclear staining for ROR t and LEF1 in LN V 1.1<sup>+</sup> (top) and V 2<sup>+</sup> (bottom) T cells from WT and *Tcf*7<sup>-/-</sup> mice shows mutually exclusive expression of the TFs and the loss of LEF1<sup>+</sup> T cells when TCF1 is non-functional. TCF1 expression, while biased, is not starkly separated from ROR t expressors in any T cell subsets. Staining controls are shown in Figure S3E. (D) Intranuclear staining for LEF1 in immature (CD24<sup>hi</sup>) and mature (CD24<sup>lo</sup>) V 2<sup>+</sup> thymocytes from WT and *Tcf*7<sup>-/-</sup> mice. See also Fig. S3.




Figure 4. ChIP assay for TF binding near the transcriptional regulatory sites of *Rorc*, *Blk*, *il17a* and *Gata3* loci

Immature V  $2^+$  and V  $2^-$  thymocytes, the immediate precursors of mature thymic effectors, were compared to in vitro differentiated control Th1 and Th17 CD4 — T cells. Analysis of mature—thymocytes was not possible due to their low numbers in mice. Graphs show quantitative PCR detection for relative enrichment of target DNA sequences from ChIP using Abs to indicated TF and control IgG (Fig. S4). The regions examined are described in Fig. S4 legend. Quantitative real-time PCR data are plotted as average percentage (%) of input +/-SD from two independent experiments. Binding of the TFs to TCF consensus sequences at the control MyoG promoter was undetectable in T cells (data not shown). See also Fig. S4.




Figure 5. Constrained impact of TCR signaling in effector specification

(A) PCA of the discriminatory gene signature of *Itk*<sup>-/-</sup> immV2 cells. PCA of the 15% most variable genes among the populations of cells shown (colors of bars and labels indicate population; MEV > 120 in at least one population; 1,433 genes). The first three principal components (PC1-PC3) are shown, along with the proportion of the total variability represented by each component (in parentheses along axes). (B) A heat map of relative gene expression of TFs in immature subsets from WT and *Itk*<sup>-/-</sup> mice. Data were gene row normalized and hierarchically clustered by gene and subset. Genes are color coded (see legend) to display relative gene expression. (C) LN cells from WT and Tcrgv2 transgenic mice (with and without normal Sox13) that express a functional V 2-J 1-C 1 (Tcr Vg2 Tg) chain in nearly all T cells (top) were analyzed for the expression of intracellular IL-17A in V 2<sup>+</sup> T cells. Representative profiles from one of two experiments are shown, each with a minimum of three/group. Similar results were observed with thymocytes. (D) progenies of c-Kit<sup>hi</sup> ETPs and c-Kit<sup>-</sup> DN3 (CD25<sup>+</sup>CD44<sup>-</sup>CD3<sup>-</sup>CD4<sup>-</sup>CD8<sup>-</sup>) precursors cultured on OP9-DL1 stromal monolayers were assayed for CCR6 and CD27 expression. Representative FACS plots of V2 cells (top) and a summary of the frequencies (bottom, Student t-test P-values) of CCR6<sup>+</sup>CD27<sup>-</sup> T 17 cells generated from ETPs (10<sup>3</sup> cells/well) or DN3 (5  $\times$ 10<sup>3</sup> cells/well) precursors are shown. Similar results were obtained with varying cell numbers/well. Average cell numbers obtained from DN1 or DN3 were  $3.5 \times 10^5$  or 4.6 $\times$  10<sup>4</sup>/well, respectively. V1/V6 = V 1.1<sup>+</sup> cells. Data are combined from 3 independent experiments, ETP n=18; DN3 n=38. See also Fig. S5.




Figure 6. TCF1 regulates the differentiation and function of GALT ILCs

(A) TCF1/LEF1 expression in CD3<sup>-</sup>CD19<sup>-</sup> mLN ILCs of adult mice. ILCs were segregated based on ROR t and IL-7R expression. CD4, NKp46, intranuclear TCF1 and LEF1 expression was assessed on the three indicated subsets. Data shown are representative profiles from one of three independent studies. (B) TCF1 expression in CD3<sup>-</sup>CD19<sup>-</sup>CD11b<sup>-</sup> mLN ILCs segregated based on NKp46 and IL-7R was analyzed. (C) TCF1 is required for the development of NCR22 cells. Intestinal LP and splenic ILCs (CD3<sup>-</sup>CD19<sup>-</sup>IL-7R<sup>+</sup>) from Tcf7-/- neonates were stained with CD4 and NKp46 to track NCR22 cells. Data shown are representative profiles from one of four studies. (D) Frequencies of CCR6+ and CD25+ in neonatal LP ILCs from Tcf7<sup>+/-</sup> heterozygotes (HET) and Tcf7<sup>-/-</sup> mice. Lines represent the mean, and Student t-test P-values are shown. Similar results in mLN. (E) Numerical reduction in the ILC subsets in the mLN of 3 wk old Tcf7<sup>-/-</sup> mice. The total cell number of IL-7R<sup>+</sup> ILCs, ROR thi and ROR to ILCs, and Nkp46<sup>+</sup> and Nkp46<sup>-</sup> ROR to ILCs is shown. Data are combined from two experiments, n=5/group. Data is represented as mean+- SEM. (F) Representative histograms showing the frequency of NCR22 cells in the mLNs of 3 wk old Tcf7-/- mice. (G) Increased expression of ROR t in Tcf7-/- ILCs. Averages of MFI (+/ -SEM) of ROR t expression in the CD3<sup>-</sup>CD19<sup>-</sup>IL-7R<sup>hi</sup> spleen cells is provided (n=5/ group; one representative experiment of four). (H) TCF1 restrains IL-17 and IL-22 production in the ILCs. Intracellular staining for IL-17 and IL-22 in the ex vivo splenic ILCs (CD3<sup>-</sup>CD19<sup>-</sup>IL-7R<sup>hi</sup>CD4<sup>+</sup>CD25<sup>+</sup>) was perfomed post-Zymosan administration. Unlike in other tissues, the number of splenic ROR t+ ILCs were marginally increased in adult Tcf7- mice. Profiles shown were obtained in two additional experiments. See also Fig. S6.